🔗 Share this article

As the US proceeds with unprecedented revisions to its vaccine schedules, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccinations during the pandemic and has zeroed in on alleged deaths following COVID-19 immunization in her recent position at the FDA.

Planned Changes to Pediatric Immunization Program

Health officials had intended to unveil major revisions to the childhood vaccination calendar in December, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of step with a large portion of the global community with little proof for improved outcomes. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to head the office this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

The appointee has little discernible background in medication creation, regulation or administrative roles, which has been standard for previous directors of the CBER. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “understand legal statutes and the science of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who led CBER have had.”

CDER has an immense portfolio at the FDA, she pointed out.

“The public just focuses on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one have to be managed,” Dr. Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the role, which oversees over 5,000 personnel. “It’s a huge management job, if you do it right,” she added.

Response and Disputed Programs

In response to inquiries about Høeg’s fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson said that the “inquiries are based on incorrect premises”.

“Her resume aligns with the duties of her role,” the representative stated, citing the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a controversial expedited medication authorization process that reportedly concerned her preceding directors. “How are these medications being selected for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy going on at the agency right now.”

In general, he stated, “the FDA seems to be moving towards less stringent rules of all drugs, with the exception of shots.”

Public Past Work on Immunizations

Regarding immunizations, Høeg has a more documented, if concerning, past, some experts observe. She released a research paper using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccines are riskier than they are.

Part of her “policy goals” for the new federal leadership featured revising regulations for recently developed shots and ending “optional” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed preventing young men from receiving Covid vaccines.

“She is an thorough true believer who commences with her conclusions and tailors the evidence to accommodate the evidence in a very disingenuous, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg joined other skeptics, {like|